Literature DB >> 31037648

Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer's Disease Studies.

Liana M de Medeiros1,2,3, Marco A De Bastiani1,2,3, Eduardo P Rico4, Patrícia Schonhofen1,2,3, Bianca Pfaffenseller1,2,5, Bianca Wollenhaupt-Aguiar1,2,5, Lucas Grun3,6, Florência Barbé-Tuana3,6, Eduardo R Zimmer3,7,8, Mauro A A Castro9, Richard B Parsons10, Fábio Klamt11,12,13.   

Abstract

Cholinergic transmission is critical to high-order brain functions such as memory, learning, and attention. Alzheimer's disease (AD) is characterized by cognitive decline associated with a specific degeneration of cholinergic neurons. No effective treatment to prevent or reverse the symptoms is known. Part of this might be due to the lack of in vitro models that effectively mimic the relevant features of AD. Here, we describe the characterization of an AD in vitro model using the SH-SY5Y cell line. Exponentially growing cells were maintained in DMEM/F12 medium and differentiation was triggered by the combination of retinoic acid (RA) and BDNF. Both acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) enzymatic activities and immunocontent were determined. For mimicking tau and amyloid-β pathology, RA + BDNF-differentiated cells were challenged with okadaic acid (OA) or soluble oligomers of amyloid-β (AβOs) and neurotoxicity was evaluated. RA + BDNF-induced differentiation resulted in remarkable neuronal morphology alterations characterized by increased neurite density. Enhanced expression and enzymatic activities of cholinergic markers were observed compared to RA-differentiation only. Combination of sublethal doses of AβOs and OA resulted in decreased neurite densities, an in vitro marker of synaptopathy. Challenging RA + BDNF-differentiated SH-SY5Y cells with the combination of sublethal doses of OA and AβO, without causing considerable decrease of cell viability, provides an in vitro model which mimics the early-stage pathophysiology of cholinergic neurons affected by AD.

Entities:  

Keywords:  BDNF; Cholinergic neurons; Retinoic acid; SH-SY5Y

Mesh:

Substances:

Year:  2019        PMID: 31037648     DOI: 10.1007/s12035-019-1605-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  56 in total

1.  The sva package for removing batch effects and other unwanted variation in high-throughput experiments.

Authors:  Jeffrey T Leek; W Evan Johnson; Hilary S Parker; Andrew E Jaffe; John D Storey
Journal:  Bioinformatics       Date:  2012-01-17       Impact factor: 6.937

2.  Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity.

Authors:  Pradeep K Kamat; Santoshkumar Tota; Gunjan Saxena; Rakesh Shukla; Chandishwar Nath
Journal:  Brain Res       Date:  2009-10-31       Impact factor: 3.252

3.  BDNF is needed for postnatal maturation of basal forebrain and neostriatum cholinergic neurons in vivo.

Authors:  N L Ward; T Hagg
Journal:  Exp Neurol       Date:  2000-04       Impact factor: 5.330

Review 4.  The cholinergic system in aging and neuronal degeneration.

Authors:  Reinhard Schliebs; Thomas Arendt
Journal:  Behav Brain Res       Date:  2010-12-09       Impact factor: 3.332

5.  Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group.

Authors:  D R Kaplan; K Matsumoto; E Lucarelli; C J Thiele
Journal:  Neuron       Date:  1993-08       Impact factor: 17.173

Review 6.  Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.

Authors:  Mark S Forman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Med       Date:  2004-10       Impact factor: 53.440

7.  Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia.

Authors:  Michel J Grothe; Christina Schuster; Florian Bauer; Helmut Heinsen; Johannes Prudlo; Stefan J Teipel
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

8.  Expression of trkB in human neuroblastoma in relation to MYCN expression and retinoic acid treatment.

Authors:  Anders Edsjö; Erik Lavenius; Helén Nilsson; Jeff C Hoehner; Per Simonsson; Lloyd A Culp; Tommy Martinsson; Christer Larsson; Sven Påhlman
Journal:  Lab Invest       Date:  2003-06       Impact factor: 5.662

9.  Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology.

Authors:  Jane Kovalevich; Dianne Langford
Journal:  Methods Mol Biol       Date:  2013

10.  Neurotrophic factors promote cholinergic differentiation in human embryonic stem cell-derived neurons.

Authors:  Mats Nilbratt; Omar Porras; Amelia Marutle; Outi Hovatta; Agneta Nordberg
Journal:  J Cell Mol Med       Date:  2009-10-03       Impact factor: 5.310

View more
  27 in total

1.  Studies on Regulation of Global Protein Profile and Cellular Bioenergetics of Differentiating SH-SY5Y Cells.

Authors:  Anuj Pandey; Sana Sarkar; Sanjeev Kumar Yadav; Smriti Singh Yadav; Saripella Srikrishna; Mohammad Haris Siddiqui; Devendra Parmar; Sanjay Yadav
Journal:  Mol Neurobiol       Date:  2022-01-13       Impact factor: 5.590

2.  High-Resolution Imaging of Mitochondria and Mitochondrial Nucleoids in Differentiated SH-SY5Y Cells.

Authors:  Emily Annuario; Kristal Ng; Alessio Vagnoni
Journal:  Methods Mol Biol       Date:  2022

3.  Functional characterization of the schizophrenia associated gene AS3MT identifies a role in neuronal development.

Authors:  Sam J Washer; Robert Flynn; Asami Oguro-Ando; Eilis Hannon; Joe Burrage; Aaron Jeffries; Jonathan Mill; Emma L Dempster
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2022-06-19       Impact factor: 3.358

4.  Neuroprotective and Antioxidant Role of Oxotremorine-M, a Non-selective Muscarinic Acetylcholine Receptors Agonist, in a Cellular Model of Alzheimer Disease.

Authors:  Giuseppa Mudò; Valentina Di Liberto; Domenico Nuzzo; Monica Frinchi; Costanza Giardina; Miriana Scordino; Mariachiara Zuccarini; Chiara De Simone; Marta Di Carlo; Natale Belluardo
Journal:  Cell Mol Neurobiol       Date:  2022-09-03       Impact factor: 4.231

5.  Alzheimer's disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells.

Authors:  Yang You; Samuel W Hersh; Roshanak Aslebagh; Scott A Shaffer; Seiko Ikezu; Jesse Mez; Kathryn L Lunetta; Mark W Logue; Lindsay A Farrer; Tsuneya Ikezu
Journal:  Aging Cell       Date:  2022-05-14       Impact factor: 11.005

6.  Blood-Brain Barrier Permeability Study of Potential Neuroprotective Compounds Recovered From Plants and Agri-Food by-Products.

Authors:  José David Sánchez-Martínez; Alberto Valdés; Rocio Gallego; Zully Jimena Suárez-Montenegro; Marina Alarcón; Elena Ibañez; Gerardo Alvarez-Rivera; Alejandro Cifuentes
Journal:  Front Nutr       Date:  2022-06-16

7.  Neuroprotective potential of terpenoid-rich extracts from orange juice by-products obtained by pressurized liquid extraction.

Authors:  José David Sánchez-Martínez; Gerardo Alvarez-Rivera; Rocio Gallego; Mariane Bittencourt Fagundes; Alberto Valdés; Jose A Mendiola; Elena Ibañez; Alejandro Cifuentes
Journal:  Food Chem X       Date:  2022-02-04

8.  Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer's Disease.

Authors:  Hafsa Amat-Ur-Rasool; Mehboob Ahmed; Shahida Hasnain; Wayne G Carter
Journal:  Brain Sci       Date:  2021-02-02

9.  Temporal Proteomic Profiling of SH-SY5Y Differentiation with Retinoic Acid Using FAIMS and Real-Time Searching.

Authors:  Tian Zhang; Steven P Gygi; Joao A Paulo
Journal:  J Proteome Res       Date:  2020-10-15       Impact factor: 4.466

10.  The Impact of Differentiation on Cytotoxicity and Insulin Sensitivity in Streptozotocin Treated SH-SY5Y Cells.

Authors:  Fruzsina Bagaméry; Kamilla Varga; Kitti Kecsmár; István Vincze; Éva Szökő; Tamás Tábi
Journal:  Neurochem Res       Date:  2021-02-22       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.